Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.009
Sell
RSI(14)
47.980
Neutral
STOCH(KDJ)(9,3,3)
54.680
Neutral
ATR(14)
0.201
High Vlolatility
CCI(14)
-28.569
Neutral
Williams %R
60.597
Sell
TRIX(12,20)
0.025
Sell
StochRSI(14)
45.443
Sell
Aquestive Therapeutics Inc
AQST4.030USD
-0.110-2.66%
Close 03/30, 16:00（ET）Quotes delayed by 15 min
98.73MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Aquestive Therapeutics Inc
Currency: USD Updated: 2026-03-27Key Insights
Aquestive Therapeutics Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 79 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 8.89.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Aquestive Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Aquestive Therapeutics Inc Highlights
StrengthsRisks
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
Growing
The company is in a growing phase, with the latest annual income totaling USD 44.55M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 44.55M.
Overvalued
The company’s latest PE is -5.13, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 68.88M shares, increasing 0.08% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 8.09K shares of this stock.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
8.889
Target Price
+114.71%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-03-27The current financial score of Aquestive Therapeutics Inc is 6.72, ranking 135 out of 157 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 13.02M, representing a year-over-year increase of 9.67%, while its net profit experienced a year-over-year increase of 86.81%.
Score
Financials
6.36
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
6.84
Operational Efficiency
6.56
Growth Potential
6.72
Shareholder Returns
7.12
Aquestive Therapeutics Inc's Company Valuation
Currency: USD Updated: 2026-03-27The current valuation score of Aquestive Therapeutics Inc is 6.41, ranking 122 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is -5.13, which is -87.34% below the recent high of -0.65 and -823.91% above the recent low of -47.40.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 79/157
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-03-27The current earnings forecast score of Aquestive Therapeutics Inc is 8.44, ranking 34 out of 157 in the Pharmaceuticals industry. The average price target is 10.50, with a high of 15.00 and a low of 8.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
8.889
Target Price
+121.12%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
174
Total
6
Median
8
Average
Company name
Ratings
Analysts
Aquestive Therapeutics Inc
AQST
9
Biogen Inc
BIIB
37
Amgen Inc
AMGN
37
Vertex Pharmaceuticals Inc
VRTX
34
Eli Lilly and Co
LLY
34
Gilead Sciences Inc
GILD
33
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-03-27The current price momentum score of Aquestive Therapeutics Inc is 7.15, ranking 30 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 4.42 and the support level at 3.69, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
4.036
Sell
MA10
4.053
Sell
MA20
4.126
Sell
MA50
3.873
Buy
MA100
4.855
Sell
MA200
4.791
Sell
Institutional Confidence
Currency: USD Updated: 2026-03-27The current institutional shareholding score of Aquestive Therapeutics Inc is 5.00, ranking 72 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 51.65%, representing a quarter-over-quarter decrease of 1.54%. The largest institutional shareholder is The Vanguard, holding a total of 5.86M shares, representing 4.81% of shares outstanding, with 17.18% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Crestline Investors, Inc.
BlackRock Institutional Trust Company, N.A.
RTW Investments L.P.
Armistice Capital LLC
EcoR1 Capital, LLC
Samsara BioCapital, LLC
State Street Investment Management (US)
Geode Capital Management, L.L.C.
1
2
Risk Assessment
Currency: USD Updated: 2026-03-27The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Aquestive Therapeutics Inc is 4.08, ranking 94 out of 157 in the Pharmaceuticals industry. The company's beta value is 1.55. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
1.51
VaR
+6.87%
240-Day Maximum Drawdown
+60.61%
240-Day Volatility
+90.80%
Return
Best Daily Return
60 days
+38.98%
120 days
+38.98%
5 years
+38.98%
Worst Daily Return
60 days
-37.04%
120 days
-37.04%
5 years
-37.04%
Sharpe Ratio
60 days
-0.95
120 days
-0.27
5 years
+0.42
Risk Assessment
Maximum Drawdown
240 days
+60.61%
3 years
+63.55%
5 years
+90.11%
Return-to-Drawdown Ratio
240 days
+1.04
3 years
+0.55
5 years
-0.00
Skewness
240 days
+0.58
3 years
+0.51
5 years
+0.46
Volatility
Realised Volatility
240 days
+90.80%
5 years
+92.01%
Standardised True Range
240 days
+7.40%
5 years
+5.53%
Downside Risk-Adjusted Return
120 days
-35.41%
240 days
-35.41%
Maximum Daily Upside Volatility
60 days
+126.75%
Maximum Daily Downside Volatility
60 days
+110.45%
Liquidity
Average Turnover Rate
60 days
+1.42%
120 days
+1.44%
5 years
--
Turnover Deviation
20 days
-13.48%
60 days
-16.41%
120 days
-14.88%
Peer Comparison
Pharmaceuticals
Aquestive Therapeutics Inc
AQST
6.67 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
UTHR
8.81 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Innoviva Inc
INVA
8.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mckesson Corp
MCK
8.40 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
CPRX
8.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Jazz Pharmaceuticals PLC
JAZZ
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
